The Verge's outside check: Claude "did not invent" scorpion antivenom
From the AI digest for 2026-10-22
What happened: The Verge (Wednesday, October 22, ~8:21 AM ET) reports that Citrini Research — an investment-research firm, not a drug developer — teamed with Anthropic to test whether an unreleased version of Claude could produce scorpion antivenom, and it could not: the model "came up with some promising starting points, but nothing close to an actual drug," experts told the outlet. Citrini admitted, per the report, that "none of us could claim to know anything about AI as it related to biology." The same day, Anthropic published an open call inviting members of the life-sciences community to apply to work with the company on special projects (anthropic.com, Wednesday, October 22, no time in capture) — the thread's first named collaborator intake.
What's genuinely new: A development of the Anthropic wet-lab thread's bio-defense leg, established Monday: on October 20 Anthropic's science blog presented Claude-designed protein binders against scorpion neurotoxins — framed against roughly 1.2 million stings a year and costly, short-supply antivenoms — as "an early step toward finding new treatments," with no independent validation named. The Verge piece is the validation layer arriving, and it arrives negative: outside experts grade the output as research starting material, not a drug, and the reporting surface adds a detail absent from the announcement — the experiment's driver was a firm self-admittedly outside the field. The thread's genre now has a third company-graded claim (enzyme system, nine-loop amplitude, quantum circuits) joined by a fourth (scorpion binders) whose first outside read contradicts the announcement's framing of a treatment pipeline. The open call is the thread's other new fact: a formal invitation to outside life-scientists to bring projects to Anthropic, published the same day the scorpion claim took its negative press check — a collaboration channel arriving unconnected, in the coverage, to the independent validation the thread's claims still lack.
Watch: Whether Anthropic responds or the scorpion work gets a journal venue; whether independent toxicology or drug-development experts weigh in on the binder designs themselves; who applies to the open call and what projects emerge from it; whether the "company-graded science claims" genre keeps drawing external press checks — the enzyme-system claim's September 27 NYT piece set that precedent.
Links: The Verge · Anthropic — open call